CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

Summary

This is an investigator-initiated dose-finding clinical study with the primary objective of evaluating the safety of CD5CART in the treatment of subjects with relapsed and refractory CD5 hematological malignancies and to explore the MTD of CD5CART treatment of relapsed and refractory subjects with CD5 hematological malignancies. At the same time, the effectiveness and pharmacokinetic characteristics of CD5CART treatment of relapsed and refractory CD5 hematological tumors in subjects were explored

Timeline

Start

2025-09-03

Primary completion

2027-05-31

Completion

2027-10-31

Drugs

Indications